|
1
|
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
|
Invest Ophthalmol Vis Sci
|
2011
|
2.53
|
|
2
|
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.
|
Arch Ophthalmol
|
2010
|
1.82
|
|
3
|
Imaging pulsatile retinal blood flow in human eye.
|
J Biomed Opt
|
2008
|
1.73
|
|
4
|
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.
|
Am J Ophthalmol
|
2009
|
1.64
|
|
5
|
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema.
|
Retina
|
2010
|
1.56
|
|
6
|
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
|
Ophthalmology
|
2013
|
1.52
|
|
7
|
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema.
|
Clin Ophthalmol
|
2011
|
1.46
|
|
8
|
Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment.
|
Retina
|
2012
|
1.46
|
|
9
|
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
|
Invest Ophthalmol Vis Sci
|
2011
|
1.46
|
|
10
|
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant.
|
Ophthalmology
|
2012
|
1.32
|
|
11
|
Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study.
|
Am J Ophthalmol
|
2007
|
1.26
|
|
12
|
Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells.
|
Retina
|
2006
|
1.25
|
|
13
|
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
|
Ophthalmology
|
2005
|
1.22
|
|
14
|
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.
|
Invest Ophthalmol Vis Sci
|
2010
|
1.17
|
|
15
|
Ocular changes after photodynamic therapy.
|
Invest Ophthalmol Vis Sci
|
2006
|
1.17
|
|
16
|
Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells.
|
Invest Ophthalmol Vis Sci
|
2006
|
1.16
|
|
17
|
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
|
Arch Ophthalmol
|
2009
|
1.13
|
|
18
|
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression.
|
Ophthalmology
|
2004
|
1.13
|
|
19
|
Ranibizumab.
|
Nat Rev Drug Discov
|
2006
|
1.08
|
|
20
|
Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells.
|
Invest Ophthalmol Vis Sci
|
2005
|
1.07
|
|
21
|
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment.
|
Ophthalmology
|
2004
|
1.07
|
|
22
|
Wet age-related macular degeneration.
|
Adv Drug Deliv Rev
|
2005
|
1.06
|
|
23
|
Uncertain compassion in using a drug before the risks and benefits are known.
|
Arch Ophthalmol
|
2006
|
1.05
|
|
24
|
Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000).
|
Am J Ophthalmol
|
2008
|
1.02
|
|
25
|
Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide.
|
Retina
|
2013
|
0.97
|
|
26
|
Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration.
|
PLoS One
|
2013
|
0.96
|
|
27
|
Intravitreous dexamethasone effects on different patterns of diabetic macular edema.
|
Arch Ophthalmol
|
2010
|
0.95
|
|
28
|
Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
|
Retina
|
2015
|
0.95
|
|
29
|
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.
|
Clin Ophthalmol
|
2010
|
0.92
|
|
30
|
Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant.
|
Am J Ophthalmol
|
2003
|
0.92
|
|
31
|
Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.
|
Retina
|
2012
|
0.92
|
|
32
|
Mitochondrial DNA damage induced by 7-ketocholesterol in human retinal pigment epithelial cells in vitro.
|
Invest Ophthalmol Vis Sci
|
2009
|
0.90
|
|
33
|
Intraocular sustained-release delivery systems for triamcinolone acetonide.
|
Pharm Res
|
2009
|
0.90
|
|
34
|
Caspase-8, -12, and -3 activation by 7-ketocholesterol in retinal neurosensory cells.
|
Invest Ophthalmol Vis Sci
|
2007
|
0.89
|
|
35
|
Effects of Benzo(e)Pyrene, a toxic component of cigarette smoke, on human retinal pigment epithelial cells in vitro.
|
Invest Ophthalmol Vis Sci
|
2008
|
0.89
|
|
36
|
Optical coherence tomography in progressive outer retinal necrosis.
|
Ophthalmic Surg Lasers Imaging
|
2006
|
0.86
|
|
37
|
Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
|
Ophthalmology
|
2006
|
0.85
|
|
38
|
The Implantable Miniature Telescope for macular degeneration.
|
Curr Opin Ophthalmol
|
2006
|
0.85
|
|
39
|
Complement factor H polymorphism in age-related macular degeneration.
|
Ophthalmology
|
2007
|
0.85
|
|
40
|
7-Ketocholesterol activates caspases-3/7, -8, and -12 in human microvascular endothelial cells in vitro.
|
Microvasc Res
|
2008
|
0.85
|
|
41
|
Activation of caspase-8 and caspase-12 pathways by 7-ketocholesterol in human retinal pigment epithelial cells.
|
Invest Ophthalmol Vis Sci
|
2006
|
0.85
|
|
42
|
Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.
|
Retina
|
2004
|
0.85
|
|
43
|
Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir.
|
J Infect Dis
|
2004
|
0.84
|
|
44
|
Faster visual recovery after 23-gauge vitrectomy compared with 20-gauge vitrectomy.
|
Retina
|
2010
|
0.83
|
|
45
|
Differential effects of nicotine on retinal and vascular cells in vitro.
|
Toxicology
|
2009
|
0.82
|
|
46
|
Macular edema. General pathophysiology.
|
Dev Ophthalmol
|
2010
|
0.81
|
|
47
|
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery.
|
Invest Ophthalmol Vis Sci
|
2009
|
0.81
|
|
48
|
Drug delivery to the posterior segment of the eye.
|
Eur J Ophthalmol
|
2011
|
0.81
|
|
49
|
Inhibition of apoptosis in human retinal pigment epithelial cells treated with benzo(e)pyrene, a toxic component of cigarette smoke.
|
Invest Ophthalmol Vis Sci
|
2009
|
0.81
|
|
50
|
Toxicity of indocyanine green (ICG) in combination with light on retinal pigment epithelial cells and neurosensory retinal cells.
|
Curr Eye Res
|
2005
|
0.80
|
|
51
|
The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence®) on retinal cells in culture.
|
J Ocul Pharmacol Ther
|
2011
|
0.80
|
|
52
|
Vitreomacular disorders: pathogenesis and treatment.
|
Retina
|
2012
|
0.80
|
|
53
|
Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro.
|
Toxicology
|
2010
|
0.80
|
|
54
|
Effects of benzo(e)pyrene on the retinal neurosensory cells and human microvascular endothelial cells in vitro.
|
Curr Eye Res
|
2009
|
0.79
|
|
55
|
Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis.
|
Expert Opin Drug Deliv
|
2010
|
0.79
|
|
56
|
Evaluation of the toxicity of triamcinolone acetonide and dexamethasone sodium phosphate on human lens epithelial cells (HLE B-3).
|
J Ocul Pharmacol Ther
|
2011
|
0.78
|
|
57
|
Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1).
|
Neurotoxicology
|
2013
|
0.78
|
|
58
|
Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone.
|
Dev Ophthalmol
|
2015
|
0.77
|
|
59
|
Effects of hydroquinone on retinal and vascular cells in vitro.
|
Indian J Ophthalmol
|
2012
|
0.77
|
|
60
|
Hyaluronidase for pharmacologic vitreolysis.
|
Dev Ophthalmol
|
2009
|
0.76
|
|
61
|
A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
|
J Ocul Pharmacol Ther
|
2013
|
0.76
|
|
62
|
In vitro evidence for mycophenolic acid dose-related cytotoxicity in human retinal cells.
|
Retina
|
2013
|
0.76
|
|
63
|
Effects of dexamethasone on human trabecular meshwork cells in vitro.
|
Graefes Arch Clin Exp Ophthalmol
|
2013
|
0.76
|
|
64
|
Protective effects of lipoic acid on chrysene-induced toxicity on Müller cells in vitro.
|
Mol Vis
|
2013
|
0.75
|
|
65
|
Vitreous surgery in pigmented rabbits using the new, noncontact wide-field viewing system.
|
Am J Ophthalmol
|
2004
|
0.75
|
|
66
|
Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel.
|
Ophthalmic Surg Lasers Imaging Retina
|
2017
|
0.75
|
|
67
|
Advances in pharmacotherapy for wet age-related macular degeneration.
|
Expert Opin Pharmacother
|
2015
|
0.75
|
|
68
|
Intracellular Edema.
|
Dev Ophthalmol
|
2017
|
0.75
|